When the Deal Closes, the Data Work Begins: How Snowflake Accelerates M&A and Divestitures in Life Sciences

The life sciences industry runs on data. Clinical trial results, regulatory submissions, manufacturing quality records, patient outcomes, supply chain traceability — these aren't just operational assets. They are the scientific and commercial backbone of every product on the market. This makes mergers, acquisitions and divestitures uniquely complicated. When a large pharmaceutical company acquires a biotech, it’s buying more than intellectual property and headcount. It's inheriting years of research, clinical data, validated systems, regulatory history and the compliance obligations that come with all of it. When a company spins off a business unit, it has to surgically separate data that has been commingled for decades, often under strict regulatory and legal timelines.

The traditional approach to this problem can be time-consuming and exceedingly expensive. Snowflake allows organizations to minimize these timelines, while also protecting the most valuable data assets. 

The life sciences M&A data problem

Most companies underestimate the data complexity of a deal until they're already in it. Some of the challenges they encounter are specific to the life sciences industry:

• Regulatory continuity: Drug development data — such as clinical trial records, adverse event reports and Corrective and Preventive Action (CAPA) documentation — must remain intact and accessible during any transition. An FDA inspection doesn't pause because two companies are integrating. Good practice (GxP)-validated systems cannot simply be migrated without documentation, validation protocols and change control.

• Patient data and privacy obligations: HIPAA in the U.S., GDPR in Europe, and a growing patchwork of regional privacy regulations mean that patient-level data cannot move freely between entities. During integration or separation, the legal basis for each data transfer must be established and documented.

• Data lineage and scientific provenance: Clinical and manufacturing data has meaning tied to its context. A bioassay result without the metadata about the instrument, analyst, lot number and protocol is scientifically worthless — and potentially a regulatory liability. Moving data without preserving lineage is not an acceptable option.

• Long data histories: Drug development spans 10 to 15 years. An acquiring company may need access to clinical data generated before the target company was even well known. Migrating these deep historical data sets is a massive undertaking under normal circumstances, let alone under the time pressure of a deal close.

• Dormant assets in acquired research portfolios: Every pharmaceutical R&D organization accumulates thousands of compounds that were deprioritized, shelved or abandoned for reasons that may no longer apply. This dormant research data, such as screening results, structure-activity relationships, Absorption, Distribution, Metabolism and Excretion (ADME) profiles, early toxicology signals or mechanism-of-action studies, represents years of invested R&D capital. But it is only valuable if it can be found, contextualized and analyzed at scale.

• Intellectual property provenance: Patent portfolios are valued in the billions, but their enforceability depends on the integrity of underlying experimental data. Lab notebooks, analytical records and synthesis logs must be locatable, attributable and tamper-evident — requirements that are difficult to satisfy when data is scattered across legacy systems or has been migrated multiple times without chain-of-custody documentation. Intellectual property is inseparable from the data that supports it. A patent claim is only as strong as the experimental evidence behind it. This creates a distinct set of M&A challenges for supporting patent prosecution and defense, freedom-to-operate analysis at scale, patent filing continuity and trade secret preservation.

• Operational continuity: The business doesn't stop during integration. Sales reps are still calling on physicians. Manufacturing is still producing products. The data that supports those functions must remain available and accurate throughout the transition.

How Snowflake addresses these challenges

Immediate data access without migration

Traditional M&A integration assumes that data must be physically moved before it can be used together — considerably the most disruptive step. Snowflake's Secure Data Sharing architecture can eliminate that requirement.

On Day 1 of a deal close, the acquiring company can be granted direct, live access to the target's Snowflake data — with no data movement, no extract, transform, load (ETL) pipeline, and no duplication. The acquired company's data stays where it lives. The parent company queries it directly, in near real time, through a secure share.

For life sciences, this matters enormously. Clinical operations teams can see the acquired company's trial status data immediately. Finance can see revenue data for combined reporting. Regulatory affairs can access submission histories. The business runs on integrated data before a single migration task is complete.

Federated architecture for regulated environments

Not every acquisition calls for full data consolidation, and in life sciences it often shouldn't. Validated systems with GxP compliance records are often better left in place, with integration happening at the reporting and analytics layer rather than the system layer.

Snowflake's multiaccount architecture supports exactly this model. Each entity maintains its own Snowflake account — its own identity, its own access controls, its own validated environment — while sharing data bidirectionally for consolidated visibility. The parent can see everything. The subsidiary operates independently. The validation state is preserved.

Clean rooms for legally sensitive integration periods

Acquisitions in life sciences often involve a period, sometimes lasting months, where the two companies cannot legally share all data with each other. Antitrust review periods, carve-out restrictions and regulatory hold requirements all create data access constraints that are legally mandated, whether or not there is a technical preference or limitation.

Snowflake Data Clean Rooms allow joint analysis without joint data access. Both parties can run secure data analysis, build combined forecasts and generate integrated reports without either side seeing the other's underlying records. The computation happens in a shared environment; the raw data never leaves either party's control. This is particularly relevant for deals involving products that are still under regulatory review or where commercial data is subject to antitrust scrutiny.

Divestitures: Separating what was built together

If acquisitions are complex, divestitures are harder. You are not adding data — you are cutting it apart.

Consider a company spinning off its diagnostics division from its pharmaceutical business. These two businesses may share a common data platform, with years of commingled records: shared customers, shared manufacturing facilities and shared clinical infrastructure. Separating that data cleanly — and doing it within the timeline and cost constraints of a deal — is one of the most difficult data engineering problems in the industry.

Snowflake addresses divestiture challenges in several ways:

• Zero-Copy Cloning: Creates an independent copy of any database, schema or table at a point in time — without duplicating storage costs until the data actually diverges. On the effective date of a divestiture, the divested entity's data domain can be cloned into a new account, giving the new standalone company a clean starting point. The original data remains untouched in the parent account. Both companies operate on their respective copies while the formal separation process continues in the background.

• Row- and column-level security: Allows surgical data restriction during transition periods. While full separation is being executed, the divested entity's users can be restricted to seeing only the data they're entitled to under the separation agreement, down to the specific rows and columns, without rebuilding the entire data model.

• Object tagging and data classification: Enables companies to inventory which data assets belong to which business unit before the separation is announced. This work — understanding what data exists, where it lives and who depends on it — typically takes months of manual effort. Snowflake's tagging and lineage capabilities compress it significantly.

• Time Travel and immutable audit trails: Create a reconstructable data history that can support patent priority documentation. Every data state is reconstructable as of any point in time within the retention window. With Snowflake Backups, customers keep critical data in Snowflake for up to 10 years in an immutable format designed to support long-duration data retention requirements.

• Cross-account data sharing: Enables patent counsel — whether internal or external — to access supporting data without requiring migration out of validated systems. Snowflake Cortex AI capabilities enable large-scale analysis of patent landscapes and internal research records to identify both risks, such as freedom-to-operate gaps, and opportunities, such as patentable subject matter in acquired data that was never filed on.

• Governance and access controls: Can help prevent trade secrets from being inadvertently disclosed during the integration period, which is particularly relevant when employees from both organizations begin working together before full legal integration.

A real life sciences pattern: The spinoff company

One pattern we see frequently in life sciences is the large-scale spinoff — a parent company divesting a segment to create a new independent entity. These transactions are announced months or years before they close, and they require the new entity to be operationally independent on Day 1.

The data challenge is substantial. The new entity needs its own data platform, its own governance model and access to years of historical data — but it cannot simply take everything from the parent. And the parent needs to continue operating on the same data without interruption.

Snowflake's architecture is designed to handle this with a combination of account replication, selective data sharing and cloning: The new entity gets its own account, receives a cloned copy of the data it's entitled to, and can access shared data from the parent via live shares during a transition period. The parent continues operating normally. The new entity builds its independent platform while still having access to shared infrastructure. Additionally, Snowflake's combination of object tagging, row-level security and access logging creates an auditable record of which data was allocated to which entity, when access was granted or revoked, and what the state of the data was at the moment of separation. This audit trail serves dual purposes: supporting the documentation requirements separation process and providing a reconstructable data record relevant to future IP questions.

A process that would have taken months of migration work can begin producing business value in a significantly shorter time frame.

Analytical capabilities that accelerate deal value

The traditional M&A integration playbook treats data consolidation as a prerequisite to analysis. First you move the data, then you build reports, then you generate insights. This sequential approach means the acquiring company often doesn't understand what it actually bought — at a granular, data-driven level — until months after close. Snowflake inverts this sequence. Because data can be queried in place through Secure Data Sharing, analytical workloads can begin immediately, allowing for the following capabilities:

• Due diligence that extends into integration: The analytical models built during due diligence such as revenue projections, pipeline probability assessments or manufacturing cost analyses can transition directly into operational dashboards after close, running against live data rather than the static snapshots used during the deal process.

• R&D portfolio optimization: With combined visibility across both companies' research programs, data science teams can quickly identify redundancies (two programs pursuing the same mechanism), synergies (a target validated by one company's genetics data and druggable by the other's chemistry) and white space opportunities.

• Commercial analytics on combined data sets: Prescription data, payer data and real-world evidence from both entities can be analyzed together to identify cross-sell opportunities, coverage gaps and competitive positioning without waiting for CRM or data warehouse consolidation.

• Safety signal detection across combined portfolios: Pharmacovigilance teams can query adverse event data across the combined product portfolio immediately, identifying potential class effects or drug-drug interactions that neither company could detect independently.

• Regulatory intelligence: Correlating both companies' regulatory submission histories, FDA meeting minutes and correspondence helps identify precedents, commitments and risks that affect the combined portfolio.

These aren't future-state capabilities. They are feasible on Day 1 for organizations running on Snowflake, because the architecture eliminates the migration prerequisite that traditionally gates analytical work.

The competitive advantage is time

In life sciences M&A, speed matters for reasons that go beyond the usual deal rationale. Synergies in commercial operations depend on integrated customer data. R&D productivity depends on the research team being able to see the acquired pipeline alongside their own. Manufacturing decisions depend on supply chain visibility that spans both entities. Every month that integration is delayed is a month of synergy value lost. Every month that a divestiture drags on is a month of operational complexity that costs both sides. As integration speed becomes a competitive differentiator in deal-making, the companies that want to execute M&A effectively in this industry will need to treat their data platform as a deal execution asset, not just an IT project. Snowflake's architecture — built around governed collaboration, federation and governance rather than consolidation and migration — aligns naturally with how life sciences deals actually need to work.

When the deal closes, the data work begins. With the right platform, it doesn't have to take as long as it used to.

Want to learn more about how Snowflake supports life sciences M&A and divestiture scenarios? Contact us.

Want to learn more about the latest Snowflake capabilities supporting life sciences organizations? Watch our Summit Encore for Life Sciences.